Company Overview of Alvine Pharmaceuticals, Inc.
Alvine Pharmaceuticals, Inc., a clinical stage company, develops biologics to target autoimmune/inflammatory diseases. It offers ALV003, a mixture of gluten-specific recombinant proteases for the treatment of celiac disease; proteases; tTG Inhibitors, a multifunctional protein with enzymatic, cell signaling, and cell adhesion activities; and HLA-DQ2 Blockers, a class II heterodimer of human leukocyte antigen. The company was incorporated in 2005 and is based in San Carlos, California.
75 Shoreway Road
San Carlos, CA 94070
Founded in 2005
Key Executives for Alvine Pharmaceuticals, Inc.
Chief Executive Office, President and Director
Scientific Founder and Director
Senior Director of Finance
Chief Business Officer and Senior Vice President
Chief Medical Officer and Senior Vice President of Development
Compensation as of Fiscal Year 2015.
Alvine Pharmaceuticals, Inc. Key Developments
Alvine Pharmaceuticals, Inc. Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease
Oct 29 13
Alvine Pharmaceuticals, Inc. announced that the first randomized study patient was dosed in the CeliAction Study(TM), a phase 2b study of its lead clinical candidate, ALV003, which is in development for the treatment of patients with celiac disease. ALV003 is an orally administered mixture of two gluten-specific proteases shown in vitro to degrade gluten, the primary immunologic trigger for celiac disease. The CeliAction Study(TM), a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging clinical study will evaluate the safety and efficacy of ALV003 at different dose levels administered over a twelve-week period in approximately 500 patients in the United States, Canada and Europe. The study is currently enrolling diagnosed celiac disease patients who are symptomatic despite attempting to follow a gluten-free diet. The study will evaluate the safety and efficacy of ALV003 administered over a twelve-week period; patients must remain on a gluten-free diet during the study. The primary efficacy endpoint for the study is the change in small intestinal mucosal morphology as measured by the change in villus height to crypt depth ratio (Vh:Cd) from baseline and week 12 assessments. Secondary endpoints are the changes in density in intestinal intraepithelial lymphocytes and celiac disease-specific symptoms during the study.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries